DB
VRDN icon

Dmitry Balyasny’s Viridian Therapeutics VRDN Stock Holding History

Dmitry Balyasny’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.5M Sell
1,279,859
-1,036,098
-45% -$16.7M 0.03% 647
2026
Q1 		$45.3M Buy
2,315,957
+1,812,089
+360% +$53.8M 0.06% 384
2025
Q4 		$15.7M Buy
503,868
+301,047
+148% +$8.26M 0.02% 842
2025
Q3 		$4.38M Buy
+202,821
New +$3.66M 0.01% 1423
2025
Q1 		– Sell
-130,721
Closed -$2.51M – 3324
2024
Q4 		$2.51M Sell
130,721
-208,368
-61% -$4.53M ﹤0.01% 1592
2024
Q3 		$7.71M Buy
+339,089
New +$5.54M 0.01% 1070
2024
Q1 		– Sell
-41,214
Closed -$898K – 3160
2023
Q4 		$898K Buy
41,214
+27,245
+195% +$430K ﹤0.01% 1730
2023
Q3 		$214K Buy
+13,969
New +$266K ﹤0.01% 2012
2023
Q1 		– Sell
-304,552
Closed -$8.9M – 3193
2022
Q4 		$8.9M Buy
304,552
+135,023
+80% +$3.11M 0.02% 787
2022
Q3 		$3.48M Buy
+169,529
New +$3.05M 0.01% 1204
2022
Q2 		– Sell
-16,303
Closed -$301K – 3219
2022
Q1 		$301K Buy
+16,303
New +$313K ﹤0.01% 1923
2021
Q3 		– Sell
-119,478
Closed -$2.19M – 2456
2021
Q2 		$2.19M Sell
119,478
-98
-0.1% -$1.68K 0.01% 981
2021
Q1 		$2M Buy
+119,576
New +$2.24M 0.01% 1023

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Dmitry Balyasny's VRDN Position: Q2 2026 in Review

Dmitry Balyasny reduced its Viridian Therapeutics (VRDN) stake by 45% in Q2 2026, selling an estimated $16.7M and leaving 1,279,859 shares worth $23.5M. The position accounts for 0.03% of the portfolio, ranked #647.

Dmitry Balyasny first reported a position in VRDN in Q1 2021 and has held it in 13 quarters since. The position peaked at $45.3M in Q1 2026. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Dmitry Balyasny held 1,279,859 shares of Viridian Therapeutics worth $23.5M as of Q2 2026.
  • Dmitry Balyasny sold 1,036,098 Viridian Therapeutics shares in Q2 2026, an estimated $16.7M.
  • Viridian Therapeutics made up 0.03% of Dmitry Balyasny's portfolio in Q2 2026, its #647 holding.
  • Dmitry Balyasny first reported a position in Viridian Therapeutics in Q1 2021 and has held it in 13 quarters since.
  • Dmitry Balyasny's Viridian Therapeutics position peaked at $45.3M in Q1 2026.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.